Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 57416592400
Loop profile: 849915

Activities

Collapse all

Employment (1)

University of Palermo: Palermo, IT

2012-11-01 to present (PROMISE Department)
Employment
Source: Self-asserted source
Mariasanta Napolitano

Education and qualifications (1)

University of L'Aquila: L’Aquila, IT

2006-11-01 to 2009-11-29 | Haematology fellow (Haematology)
Qualification
Source: Self-asserted source
Mariasanta Napolitano

Peer review (76 reviews for 28 publications/grants)

Review activity for Annals of hematology. (2)
Review activity for Annals of hematology. (2)
Review activity for British journal of haematology. (1)
Review activity for Cancer medicine. (1)
Review activity for Cancers. (2)
Review activity for Clinical and applied thrombosis/hemostasis. (3)
Review activity for Clinical case reports. (1)
Review activity for Drugs & therapy perspectives (2)
Review activity for EJHaem. (3)
Review activity for Expert opinion on drug metabolism and toxicology (1)
Review activity for Expert review of hematology (2)
Review activity for Haemophilia. (28)
Review activity for International journal of environmental research and public health (1)
Review activity for International journal of molecular sciences. (3)
Review activity for Journal of blood medicine (2)
Review activity for Journal of clinical medicine. (4)
Review activity for Journal of international medical research. (2)
Review activity for Journal of medical virology. (1)
Review activity for Journal of obstetrics and gynaecology (1)
Review activity for Journal of patient experience. (2)
Review activity for Mediterranean Journal of Hematology and Infectious Diseases. (1)
Review activity for Orphanet journal of rare diseases. (2)
Review activity for PloS one. (2)
Review activity for Scandinavian journal of rheumatology. (1)
Review activity for The Italian journal of pediatrics. (1)
Review activity for Therapeutic advances in drug safety. (2)
Review activity for Therapeutics and clinical risk management (1)
Review activity for Thrombosis and haemostasis. (2)
How many people are using ORCID?